A ReaL World Study of DS-8201
NCT06945224 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2025-04-25
Summary
A ReaL world study of DS-8201
Conditions
- Breast Cancer Metastatic
- Treatment Efficacy
Sponsors & Collaborators
-
Fudan University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-12-01
- Primary Completion
- 2025-06-30
- Completion
- 2025-06-30
Countries
- China
Study Locations
More Related Trials
-
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)
NCT03248492 ·Status: TERMINATED ·Phase: PHASE2
-
Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
NCT06344793 ·Status: COMPLETED
-
A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases
NCT06088056 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
NCT04294628 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer
NCT07035353 ·Status: NOT_YET_RECRUITING
-
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients
NCT05953168 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer
NCT06503380 ·Status: RECRUITING
-
Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients
NCT01232062 ·Status: COMPLETED
-
Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy
NCT05285332 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer
NCT02137083 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
NCT04514419 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
NCT07073755 ·Status: RECRUITING
-
Study the Role of Stem Cell in Curing Drug Induced Liver Injury in Metastatic Breast Cancer (MBC)
NCT01231022 ·Status: COMPLETED
-
Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
NCT06033287 ·Status: RECRUITING
-
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
NCT07152782 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Chimeric Antigen Receptor-Modified T Cells for Breast Cancer
NCT02547961 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy
NCT06161922 ·Status: RECRUITING
-
A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
NCT02896855 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer
NCT06791161 ·Status: ENROLLING_BY_INVITATION
-
A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC
NCT04215003 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen
NCT05731258 ·Status: RECRUITING
-
Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
NCT06245824 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer
NCT00001493 ·Status: COMPLETED ·Phase: PHASE2